A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo
A legfontosabb adatok
- Ki végzi
- Dermavon Holdings Limited
- Hol
- Beijing, Changchun, Changde, Chengde, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Jingzhou, Kunming, Nanchang, Nanning, Nanyang, Ningbo, Sanmenxia, Shanghai, Shenzhen, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Ürümqi, Wuhan, Xi'an, Xingtai, Zhengzhou és Zhenjiang (Kína)Mind a 44 helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 174 fő, tervezett
- Kezdés
- 2026. nov.
- Várható befejezés
- 2028. jún.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Povorcitinib phosphate
- Placebo
- A regiszteradat frissítve
- 2026. október 8.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for Chinese adults with nonsegmental vitiligo whom the study doctor judges fit to take a whole-body (systemic) treatment. It compares povorcitinib phosphate tablets with placebo for 52 weeks.
- Életkor
- 18 years or older
- Nem
- Any sex
- A betegség stádiuma
- Nonsegmental vitiligo covering at least 5% of the body (T-BSA ≥5%, T-VASI ≥4), with face involvement (F-BSA ≥0.5%, F-VASI ≥0.5%).
- Korábbi kezelés
- People must stop all vitiligo treatments during the study. People whose vitiligo or another inflammatory disease did not respond to any JAK inhibitor cannot join. People who ever used skin-lightening agents such as hydroquinone monobenzyl ether, or had surgery for vitiligo, cannot join. Waiting periods apply after other treatments, such as 8 weeks after laser therapy or phototherapy.
A részvétel fő kizáró okai
- Other types of vitiligo, such as segmental vitiligo, or other skin conditions that cause light patches
- Pregnancy, breastfeeding, or plans to become pregnant
- History of blood clots, serious heart disease, low platelets or bleeding problems
- Cancer now or in the past, except well-treated basal or squamous cell skin cancer
- Tuberculosis, HIV, active hepatitis B or C, or chronic or repeated infections
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Able to understand and willing to sign written informed consent
- Age ≥18 years at consent; any sex
- Clinical diagnosis of nonsegmental vitiligo, with all of the following at screening and baseline: T-BSA ≥5%; T-VASI ≥4; F-BSA ≥0.5%; F-VASI ≥0.5%; and Considered suitable for systemic therapy by the investigator.Note: When assessing body surface area (BSA) and the Vitiligo Area Scoring Index (VASI), a Wood's lamp must be used in a darkroom. 4. Agrees to discontinue all vitiligo treatments from screening through the last safety follow-up visit
- Agree to adopt effective contraceptive measures and meet the following requirements:
- Men with fertility potential: use highly effective contraception within at least 90 days from screening to the last dose of medication; do not donate sperm
- Women with fertility potential (WOCBP): negative serum pregnancy test at screening, and negative urine pregnancy test prior to the first dose; use highly effective contraception within at least 90 days from screening to the last dose of medication; do not donate oocytes
- Women without fertility potential (as defined in Appendix A) are exempt from the above restrictions; Willing and able to comply with study procedures, including standardized lesion photography
Ki nem vehet részt
- Spontaneous and pronounced repigmentation occurring within the 6 months prior to screening (e.g., evident repigmentation without any prior treatment, as determined by the investigator)
- Current or prior use of decolorizing agents such as hydroquinone monobenzyl ether (including Benoquin® [Monohydroquinone])
- The subject had used laser therapy or phototherapy (including tanning beds) within the 8 weeks preceding the first dose
- The subject must have experienced severe trauma or major surgery within 30 days prior to the screening visit, as judged by the investigator
- The subject must have a history of failed treatment with any systemic or topical JAK inhibitor for vitiligo or other inflammatory diseases
- The washout period prior to the first dose must meet one of the following criteria:; For any investigational or experimental therapy, <12 weeks or 5 half-lives (if known), whichever is longer; For immunomodulatory biologics, <12 weeks or 5 half-lives (if known), whichever is longer; For live vaccines, <8 weeks, or if the subject is scheduled to receive a live vaccine during the study period or within 8 weeks after the last dose of the study drug; Systemic immunosuppressive or immunomodulatory small-molecule agents (e.g., corticosteroids [oral or intravenous], methotrexate, cyclosporine, dapsone, azathioprine, etc.) must have been discontinued for <4 weeks; Note: The use of inhaled or nasal corticosteroids is permitted. Note: For non-cutaneous conditions (e.g., exacerbation of asthma, bronchitis), if judged acceptable by the investigator and the sponsor (or their designated personnel), prednisone-equivalent doses ≤10 mg/day may be used for ≤7 consecutive days; For any topical or systemic JAK inhibitor: <4 weeks; For traditional Chinese medicines/proprietary Chinese medicines used in the treatment of vitiligo: <4 weeks; For any topical treatment of vitiligo other than JAK inhibitors: <2 weeks; For any oral or topical PDE4 inhibitor (e.g., apremilast, criborol): <1 week; For potent systemic CYP3A4 inhibitors and potent systemic CYP3A4 inducers: <1 week or 5 half-lives (if known), whichever is longer. Examples include, but are not limited to: fluconazole, itraconazole, carbamazepine, ritonavir, St. John's wort, grapefruit/grapefruit juice
- Patients clinically diagnosed with other types of vitiligo (e.g., segmental vitiligo) or other hypopigmentary skin disorders (including but not limited to piebaldism, pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive patchy hypopigmentation, nevus anemicus, chemical leukoderma, and pityriasis versicolor)
- History of melanocyte-keratinocyte transplantation or other surgical treatments for vitiligo
- The subject had poorly controlled thyroid disease as assessed by the investigator and/or a specialist, or exhibited clinically significant abnormalities in thyroid-stimulating hormone (TSH) or free T3 and free T4 during screening, indicating active thyroid dysfunction
- The subject must also have a history of clinically significant drug or alcohol abuse within the 6 months preceding the screening visit, as judged by the investigator
- Evidence of Mycobacterium tuberculosis infection (i.e., tuberculosis) is present
- A positive anti-HIV antibody test result is present
- Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or risk of HBV or HCV relapse, is present
- The participant has a known hypersensitivity to povotuxin phosphate or to any excipient contained in povotuxin phosphate tablets
- The following concomitant diseases or past medical history are present:; current or past history of thrombocytopenia, coagulopathy, or platelet dysfunction; or current use of anticoagulants or medications known to induce thrombocytopenia; History of venous thrombosis or arterial embolism, including but not limited to deep vein thrombosis, pulmonary embolism, moderate to severe heart failure [NYHA class III or IV], cerebrovascular accident within 6 months prior to screening, myocardial infarction, coronary stent implantation, or coronary artery bypass grafting [CABG]; Diagnosis of other serious cardiovascular diseases, including but not limited to angina pectoris, peripheral arterial disease, or uncontrolled arrhythmias such as atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, or various forms of myocarditis; Uncontrolled hypertension (as assessed by the investigator); Disabled patients requiring bed rest or wheelchair use; Patients who have undergone organ transplantation; Presence of any malignant tumor or history of malignant tumor (excluding well-treated cases such as basal cell carcinoma or squamous cell carcinoma of the skin); Conditions that may interfere with drug absorption, including but not limited to short bowel syndrome; Chronic or recurrent infectious diseases, including but not limited to chronic renal infections, chronic thoracic infections (e.g., bronchiectasis), recurrent urinary tract infections (recurrent pyelonephritis or chronic persistent cystitis), fungal infections, prior history of prosthetic joint infection, or open, exudative, or infected skin wounds or ulcers. Current or past history of disseminated herpes zoster, or recurrent herpes zoster (with more than one episode); Current or past history of disseminated herpes simplex; Having received systemic anti-infective therapy within 4 weeks prior to the first dose, or having any active infection judged by the investigator to be unsuitable for participation in this study; Albinism; Any other clinically significant disease, other than vitiligo, judged by the investigator to be unsuitable for participation in this clinical study
- During screening, the 12-lead electrocardiogram should demonstrate clinically significant abnormalities requiring treatment (e.g., acute myocardial infarction, severe tachyarrhythmias or bradyarrhythmias), or indicate the presence of serious underlying cardiac disease (e.g., cardiomyopathy, severe congenital heart disease, diffuse low voltage in all leads, Wolff-Parkinson-White syndrome), or show a QTc interval>480 ms
- During screening visits, any of the following abnormal laboratory test results shall be considered:; serum aspartate aminotransferase (AST)> 2×ULN; serum alanine aminotransferase (ALT)> 2×ULN; total bilirubin (TBIL) ≥ 1.5×ULN (trial participants with a history of Gilbert syndrome who have TBIL ≥ 1.5×ULN but direct bilirubin (DBIL) ≤ ULN shall not be excluded based on this criterion); absolute neutrophil count (ANC) <1.5×10⁹/L; platelet count (PLT) <90×10⁹/L; hemoglobin (HGB) <90 g/L; other laboratory abnormalities that are clinically significant and judged by the investigators to render the participant unsuitable for enrollment; Note: If a laboratory test result exceeds the threshold specified in the protocol but is suspected to be transient (e.g., due to physiological factors or assay variability), or only marginally exceeds the threshold, the test may be repeated once during the screening period (only once is permitted) to clarify the result. If the repeat test still exceeds the threshold, the trial participant shall be excluded from screening
- Any condition-as judged by the investigator-that could compromise the participant's full participation in the study (including administration of the study medication and attendance at scheduled study visits), pose a significant risk to the participant, or interfere with the interpretation of study data, laboratory results, or screening assessment outcomes
- Following screening evaluation, white hair appears on more than 33% of the facial body surface area affected by vitiligo lesions; or white hair appears on more than 33% of the total body surface area (including the face) affected by vitiligo lesions
- The subject had used dihydroxyacetone (commonly found in tanning products) within the 4 weeks preceding the first dose
- The subject was pregnant or breastfeeding, or had plans to become pregnant during the study period
Helyszínek itt: Kína
- Beijing Chao-Yang Hospital, Capital Medical UniversityBeijing, KínaContact: Fang LiuToborzás még nem indult
- Beijing Friendship Hospital, Capital Medical UniversityBeijing, KínaContact: Fenglin CuiToborzás még nem indult
- Beijing Tongren Hospital, Capital Medical UniversityBeijing, KínaContact: Aihua WeiToborzás még nem indult
- The First Hospital of Jilin UniversityChangchun, KínaContact: Shanshan LiToborzás még nem indult
- Changde First People's HospitalChangde, KínaContact: Jianjian ZhuToborzás még nem indult
- The Affiliated Hospital of Chengde Medical UniversityChengde, KínaContact: Xinsuo DuanToborzás még nem indult
- Chengdu Second People's HospitalChengdu, KínaContact: Yanyan FengToborzás még nem indult
- The First Affiliated Hospital of Chongqing Medical UniversityChongqing, KínaContact: Jin ChenToborzás még nem indult
- Dalian Dermatosis HospitalDalian, KínaContact: Chengzhi LüToborzás még nem indult
- The First Affiliated Hospital of Dalian Medical UniversityDalian, KínaContact: Zhiqi SongToborzás még nem indult
- Dermatology Hospital of Southern Medical UniversityGuangzhou, KínaContact: Bin YangToborzás még nem indult
- Dongguan People's HospitalGuangzhou, KínaContact: Changxing LiToborzás még nem indult
- The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, KínaContact: Zhongrong LiuToborzás még nem indult
- The First Affiliated Hospital, Sun Yat-sen UniversityGuangzhou, KínaContact: Jiande HanToborzás még nem indult
- The Third Affiliated Hospital,Sun Yat-Sen UniversityGuangzhou, KínaContact: Qingfang XuToborzás még nem indult
- Hangzhou Third People's HospitalHangzhou, KínaContact: Aie XuToborzás még nem indult
- The Second Affiliated Hospital Of Anhui Medical UniversityHefei, KínaContact: Chunjun YangToborzás még nem indult
- Jiangmen Central HospitalJiangmen, KínaContact: Wei QinToborzás még nem indult
- Qilu Hospital of Shandong UniversityJinan, KínaContact: Ying LiToborzás még nem indult
- Shandong Provincial Institute of Dermatology and VenereologyJinan, KínaContact: Furen ZhangToborzás még nem indult
- Jingzhou Central HospitalJingzhou, KínaContact: Yi SunToborzás még nem indult
- The First Affiliated Hospital of Kunming Medical UniversityKunming, KínaContact: Dongjie SunToborzás még nem indult
- The Second Affiliated Hospital of Nanchang UniversityNanchang, KínaContact: Ougen LiuToborzás még nem indult
- The First Affiliated Hospital of Guangxi Medical UniversityNanning, KínaContact: Sijian WenToborzás még nem indult
- Nanyang First People's HospitalNanyang, KínaContact: Hui MaToborzás még nem indult
- The First Affiliated Hospital of Ningbo UniversityNingbo, KínaContact: Bingjiang LinToborzás még nem indult
- Sanmenxia Central HospitalSanmenxia, KínaContact: Xiaojing ZhengToborzás még nem indult
- Shanghai General HospitalShanghai, KínaContact: Zhouwei WuToborzás még nem indult
- Shenzhen People's HospitalShenzhen, KínaContact: Jianglin ZhangToborzás még nem indult
- Shenzhen Second People's HospitalShenzhen, KínaContact: Cuihong LianToborzás még nem indult
- Affiliated Central Hospital of Shenyang Medical CollegeShenyang, KínaContact: Xiaodong LiToborzás még nem indult
- Shenyang Hospital of Traditional Chinese and Western Medicine (Shenyang No. 7 People's Hospital; Shenyang Institute of Dermatology)Shenyang, KínaContact: Mingqiang SunToborzás még nem indult
- The First Hospital of Hebei Medical UniversityShijiazhuang, KínaContact: Guoqiang ZhangToborzás még nem indult
- The Second Hospital of Hebei Medical UniversityShijiazhuang, KínaContact: Yanling LiToborzás még nem indult
- Suzhou Municipal HospitalSuzhou, KínaContact: Jun GuToborzás még nem indult
- Shanxi Bethune HospitalTaiyuan, KínaContact: Yuying KangToborzás még nem indult
- The First Hospital of Shanxi Medical UniversityTaiyuan, KínaContact: Shuping GuoToborzás még nem indult
- The People's Hospital of Xinjiang Uygur Autonomous RegionÜrümqi, KínaContact: Xiaojing KangToborzás még nem indult
- Wuhan Hospital of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital)Wuhan, KínaContact: Liuqing ChenToborzás még nem indult
- The First Affiliated Hospital of Air Force Military Medical UniversityXi'an, KínaContact: Chunying LiToborzás még nem indult
- Xingtai People's HospitalXingtai, KínaContact: Fang ChengToborzás még nem indult
- Henan Provincial People's HospitalZhengzhou, KínaContact: Hongwei LiuToborzás még nem indult
- Zhengzhou Central HospitalZhengzhou, KínaContact: Zixue ChenToborzás még nem indult
- The Affiliated Hospital of Jiangsu UniversityZhenjiang, KínaContact: Hui XuToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This Phase 3 study will evaluate the efficacy and safety of oral povorcitinib phosphate compared with placebo in Chinese adults with nonsegmental vitiligo who are considered suitable for systemic therapy. Approximately 174 participants will be randomized 1:1 to povorcitinib phosphate 30 mg once daily or matching placebo for 52 weeks, followed by a 4-week safety follow-up. The primary efficacy assessment is proportion of participants achieving ≥75% improvement from baseline in face vitiligo area scoring index at Week 52.
A vizsgálat 2 csoportja
- Povorcitinib phosphateA vizsgált kezelés
- PlaceboPlacebo, összehasonlításként
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Povorcitinib Phosphate Tablets in Chinese Adult Participants With Nonsegmental Vitiligo
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. október 8.